179 related articles for article (PubMed ID: 28403086)
1. A case report of apatinib in treating osteosarcoma with pulmonary metastases.
Zhou Y; Zhang W; Tang F; Luo Y; Min L; Zhang W; Shi R; Duan H; Tu C
Medicine (Baltimore); 2017 Apr; 96(15):e6578. PubMed ID: 28403086
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
3. Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.
Zhao C; Zhang Q; Qiao W
Medicine (Baltimore); 2017 Dec; 96(50):e9276. PubMed ID: 29390380
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: A single-center observational study.
Zheng K; Xu M; Wang L; Yu X
Medicine (Baltimore); 2018 Aug; 97(31):e11734. PubMed ID: 30075583
[TBL] [Abstract][Full Text] [Related]
5. Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review.
Zheng Z; Wang H; Jiang H; Chen E; Zhang J; Xie X
Medicine (Baltimore); 2017 Nov; 96(45):e8507. PubMed ID: 29137048
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.
Zhu B; Li J; Xie Q; Diao L; Gai L; Yang W
Cancer Biol Ther; 2018 Mar; 19(3):198-204. PubMed ID: 29261005
[TBL] [Abstract][Full Text] [Related]
7. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients.
Yao H; Chen X; Tan X
BMC Cancer; 2021 Apr; 21(1):449. PubMed ID: 33892656
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
10. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
Liu Z; Ou W; Li N; Wang SY
Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
[TBL] [Abstract][Full Text] [Related]
11. Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Hui K; Hu C; Ren Y; Jiang X
Medicine (Baltimore); 2017 Nov; 96(47):e8725. PubMed ID: 29381963
[TBL] [Abstract][Full Text] [Related]
12. Apatinib treatment in extensive metastatic advanced thymic carcinoma.
He Y; Liu S; E M; Wang C; Shi M; Liu G; Abiyasi N
J Biol Regul Homeost Agents; 2018; 32(3):693-697. PubMed ID: 29921401
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
[TBL] [Abstract][Full Text] [Related]
15. The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.
Ding L; Li QJ; You KY; Jiang ZM; Yao HR
Medicine (Baltimore); 2016 May; 95(20):e3598. PubMed ID: 27196461
[TBL] [Abstract][Full Text] [Related]
16. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
17. The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report.
Han Z; He Z; Wang C; Wang Q
Medicine (Baltimore); 2018 Dec; 97(49):e13388. PubMed ID: 30544412
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report.
Zhang Y; Yin S; Jia Y; Qin L
Medicine (Baltimore); 2020 Aug; 99(33):e21600. PubMed ID: 32872014
[TBL] [Abstract][Full Text] [Related]
19. [Apatinib as Salvage Therapy for Heavily Pretreated SCLC].
Li F; Tao H
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):565-570. PubMed ID: 30037379
[TBL] [Abstract][Full Text] [Related]
20. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]